[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648496":3},{"organization":4,"armGroups":7,"interventions":47,"overallOfficials":53,"centralContacts":69,"locations":75,"responsibleParty":100,"collaborators":53,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":53,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":53,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":78,"whyStopped":53,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,15,19,25,29,34,38,43],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1-Treatment Sequence A","EXPERIMENTAL","Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose A) in Period 2.",[13,14],"Drug: Elecoglipron Reference Formulation Dose A","Drug: Elecoglipron Test formulation 1 Dose A",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 1 - Treatment Sequence B","Participant will receive a single dose of elecoglipron test formulation 1 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 2 - Treatment Sequence C","Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose B) in Period 2.",[23,24],"Drug: Elecoglipron Reference Formulation Dose B","Drug: Elecoglipron Test formulation 1 Dose B",{"label":26,"type":10,"description":27,"interventionNames":28},"Cohort 2 - Treatment Sequence D","Participant will receive a single dose of elecoglipron test formulation 1 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.",[23,24],{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort 3 - Treatment Sequence E","Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose A) in Period 2.",[13,33],"Drug: Elecoglipron Test formulation 2 Dose A",{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort 3 - Treatment Sequence F","Participant will receive a single dose of elecoglipron test formulation 2 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.",[13,33],{"label":39,"type":10,"description":40,"interventionNames":41},"Cohort 4 - Treatment Sequence G","Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose B) in Period 2.",[23,42],"Drug: Elecoglipron Test formulation 2 Dose B",{"label":44,"type":10,"description":45,"interventionNames":46},"Cohort 4 - Treatment Sequence H","Participant will receive a single dose of elecoglipron test formulation 2 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.",[23,42],[48,54,57,60,63,66],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"DRUG","Elecoglipron Reference Formulation Dose A","Elecoglipron tablets will be administered orally.",[16,9,30,35],null,{"type":49,"name":55,"description":51,"armGroupLabels":56,"otherNames":53},"Elecoglipron Test formulation 1 Dose A",[16,9],{"type":49,"name":58,"description":51,"armGroupLabels":59,"otherNames":53},"Elecoglipron Reference Formulation Dose B",[20,26,39,44],{"type":49,"name":61,"description":51,"armGroupLabels":62,"otherNames":53},"Elecoglipron Test formulation 1 Dose B",[20,26],{"type":49,"name":64,"description":51,"armGroupLabels":65,"otherNames":53},"Elecoglipron Test formulation 2 Dose A",[30,35],{"type":49,"name":67,"description":51,"armGroupLabels":68,"otherNames":53},"Elecoglipron Test formulation 2 Dose B",[39,44],[70],{"name":71,"role":72,"phone":73,"phoneExt":53,"email":74},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[76,90],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":53},"Research Site","RECRUITING","Glendale","California","91206","United States","US",{"type":85,"coordinates":86},"Point",[87,88],-118.25508,34.14251,{"lat":88,"lon":87},{"facility":77,"status":91,"city":92,"state":93,"zip":94,"country":82,"countryCode":83,"cosmosGeoPoint":95,"geoPoint":99,"contacts":53},"NOT_YET_RECRUITING","Brooklyn","Maryland","21225",{"type":85,"coordinates":96},[97,98],-76.60219,39.23039,{"lat":98,"lon":97},{"type":101,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR","100648496","phase-1-a-study-to-investigate-the-relative-bioavailability-and-safety-of-different-oral-formulations-of-elecoglipron-in-healthy-participants-100648496",false,"NCT07723833","A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants","A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants","Inclusion Criteria:\n\n* Healthy participants with suitable veins for cannulation or repeated venipuncture.\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.\n* Females of non-childbearing potential must be confirmed at screening visit as postmenopausal or have documentation of irreversible surgical sterilization.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.\n* Have a body mass index between 18.5 and 30 kg\u002Fm2 inclusive and weigh at least 50 kg.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History of acute pancreatitis.\n* History or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma.\n* Participants who have previously received elecoglipron within the last 3 months.",true,"ALL","18 Years","55 Years",{"count":114,"type":115},152,"ESTIMATED","INTERVENTIONAL",[118],"PHASE1","The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.",[121],"Healthy Participants",[123,124,125,126,127,128,129,130],"Glucagon-like peptide receptor agonist (GLP-1RA)","Type 2 Diabetes Mellitus (T2DM)","Glucose Metabolism Disorders","Metabolic Diseases","Obesity management","Pharmacokinetics","Relative bioavailability","Obesity and Related Co-morbidities","2026-08-19",{"date":133,"type":134},"2026-08-20","ACTUAL",{"date":136,"type":134},"2026-07-27",{"date":138,"type":115},"2026-11-18",{"name":5,"class":6},2]